Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Conjugates enter their first clinical trials
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
